Ginkgo Bioworks Holdings, Inc.
DNA
$7.08
$0.395.83%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.40M | 38.84M | 49.60M | 48.32M | 43.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.40M | 38.84M | 49.60M | 48.32M | 43.85M |
| Cost of Revenue | 7.30M | 12.80M | 14.82M | 12.05M | 9.62M |
| Gross Profit | 26.10M | 26.04M | 34.78M | 36.27M | 34.23M |
| SG&A Expenses | 46.01M | 44.95M | 43.28M | 49.04M | 51.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.44M | 127.11M | 111.47M | 132.01M | 137.98M |
| Operating Income | -70.05M | -88.27M | -61.87M | -83.70M | -94.14M |
| Income Before Tax | -81.39M | -80.75M | -60.58M | -90.87M | -107.86M |
| Income Tax Expenses | -643.00K | 1.00K | -283.00K | 88.00K | -325.00K |
| Earnings from Continuing Operations | -80.75M | -80.76M | -60.30M | -90.96M | -107.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.75M | -80.76M | -60.30M | -90.96M | -107.53M |
| EBIT | -70.05M | -88.27M | -61.87M | -83.70M | -94.14M |
| EBITDA | -61.08M | -88.10M | -46.07M | -68.33M | -83.19M |
| EPS Basic | -1.41 | -1.45 | -1.10 | -1.68 | -2.00 |
| Normalized Basic EPS | -0.68 | -0.93 | -0.65 | -0.94 | -1.00 |
| EPS Diluted | -1.42 | -1.45 | -1.10 | -1.68 | -2.00 |
| Normalized Diluted EPS | -0.68 | -0.93 | -0.65 | -0.94 | -1.00 |
| Average Basic Shares Outstanding | 57.08M | 55.63M | 54.86M | 54.24M | 53.81M |
| Average Diluted Shares Outstanding | 57.08M | 55.63M | 54.86M | 54.24M | 53.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |